Hisataka Maki

Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial

Marius M. Hoeper, Hikmet Al‐Hiti, Raymond L. Benza et al. · The Lancet Respiratory Medicine · 2021 · 151 citations

Hypertension, Pulmonary Arterial Hypertension, Phosphodiesterase-5 Inhibitors +11

Novel Criteria of Urine Osmolality Effectively Predict Response to Tolvaptan in Decompensated Heart Failure Patients

Teruhiko Imamura, Koichiro Kinugawa, Taro Shiga et al. · Circulation Journal · 2012 · 113 citations · Full text

Increased Urine Aquaporin-2 Relative to Plasma Arginine Vasopressin Is a Novel Marker of Response to Tolvaptan in Patients With Decompensated Heart Failure

Teruhiko Imamura, Koichiro Kinugawa, Takeo Fujino et al. · Circulation Journal · 2014 · 87 citations · Full text

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension

Takeshi Ogo, Hiroto Shimokawahara, Hideyuki Kinoshita et al. · European Respiratory Journal · 2021 · 67 citations · Full text

Late-Onset Right Ventricular Failure in Patients With Preoperative Small Left Ventricle After Implantation of Continuous Flow Left Ventricular Assist Device

Teruhiko Imamura, Koichiro Kinugawa, Naoko Kato et al. · Circulation Journal · 2014 · 65 citations · Full text